MSTX - .11 Down .475 so far. Mast Therapeutics Drops 78% in Post-Market; Phase 3 Drug to Treat Sickle Cell Disease Fails to Meet Endpoint stockcharts.com/c-sc/sc?s=MSTX&p=D&b=5&g=0&i=t73303283693&r=1474464952619